Searched for
HUMAN RECOMBINANT INSULIN
The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...- Biocon's Bengaluru drug manufacturing facility gets 'Voluntary Action Indicated' classificationBiocon Biologics' drug substance facility in Bengaluru has been classified as Voluntary Action Indicated (VAI) by the USFDA. This classific...
- Biocon Biologics' arm gets USD 90 mn contract from Malaysian government for supply of insulinsBiocon Biologics, a part of Biocon Ltd, has created a Centre of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to m...
- Biocon Biologics wins $90 mn contract from Malaysia to supply human insulinBiocon has a insulins manufacturing facility is Malaysia at Johor which has been approved by the National Pharmaceutical Regulatory Authori...
- Biocon Biologics' biosimilar human insulin gets backing from EMA expert panelThe EMA's Committee for Medicinal Products for Human Use (CHMP) opinion will be considered by the European Commission. "The European Commis...
- Eris enters JV with MJ Pharma to commercialise insulins in domestic marketThe business of the joint venture will be kickstarted with the launch of human insulin in the fourth quarter of FY22.
- Biocon partners with Voluntis to develop digital therapeutics for diabetes patientsThe licensing agreement, signed between Biocon Biologics’ subsidiary Biocon Sdn. Bhd., Malaysia and Voluntis, would make Biocon Biologics o...
- Biocon to reduce insulin prices to 10 cents per dayKiran Mazumdar Shaw, chairperson and managing director, Biocon said accessibility of insulin has been a major concern over the years due to...
- Biocon's Malaysian arm gets EU GMP certification for insulin manufacturing facilityThe integrated insulins facility in Malaysia manufactures drug substance and drug products in vials, cartridges, and insulin delivery devic...
- Biocon bags Rs 460-crore contract from MalaysiaThe drug, manufactured by Biocon at its large scale biopharmaceutical facility in Johor, Malaysia, is the country's first locally manufactu...
- Biocon links with Mexico's PiSA to tap US insulin marketBiocon said it has entered into a co-development and commercialization alliance with PiSA of Mexico for recombinant human insulin aimed at ...
- Biocon is at a strong price disadvantage to global players : Kiran Mazumdar ShawThe National Pharmaceutical Pricing Authority has allowed pharma cos to increase the price of insulin drugs. Kiran Mazumdar Shaw, Chairpers...
- Market gives thumbs up to Biocon's deal with PfizerThe Bangalore-based firm’s scrip opened at Rs 445, reached an intra-day high of Rs 464.6 before closing at Rs 455, up 12.97% over Monday’s ...
- Wockhardt opens lower after drug launchWockhardt stock opened the day lower at Rs 94.50 on news that it has launched its new insulin (Glaritus)that has a global market of $2 bill...
- Biocon picks up 70% in German pharma co AxiCorp for e30 mnThe deal will enable the Bangalore-based player to market its injectible insulin, generics, biosimilars and biologics in Europe.
- Biocon buys 70 pc of Germany's AxiCorpBiotechnology firm Biocon on Monday announced the acquisition of a 70 per cent stake in German pharmaceutical company, AxiCorp GmbH, for Eu...
- Wockhardt plans to restart production of human insulinWockhardt is planning to restart production of human recombinant insulin Wosulin (50:50), for which the State Food and Drug Administration ...
- Biocon to make UK, US forayIndia’s Biocon is soon to establish a beachhead in the UK, and is setting up an office in London.
- Biocon to establish a beachhead in the UKIndia's Biocon is soon to establish a beachhead in the UK, and is setting up an office in London.
- Wockhardt in talks to out-license research moleculesWockhardt is likely to out-license some of its research molecules to global pharma companies.
Load More
